Ipsen presents full data showing ‘survival profit’ in pancreatic cancer in phase 3 trial

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) introduced full data from a phase 3 trial showing that its drug Onivyde helped enhance total survival (OS) and progression-free survival (PFS) in sufferers with a kind of pancreatic cancer.

The French drugmaker had initially reported

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!